Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis’ Semuloparin May Have Safety Advantage For ODAC To Consider

This article was originally published in The Pink Sheet Daily

Executive Summary

Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.

You may also be interested in...

Lacking A Clear Disease Setting, Sanofi’s Semuloparin Fails ODAC Vote

It isn’t clear to either FDA or the Oncologic Drugs Advisory Committee what specific cancer chemotherapy setting would be the most useful for Sanofi-Aventis’ semuloparin, a low molecular weight heparin intended to prevent venous thromboembolism.

Sanofi-Aventis’ Semuloparin To Face Skeptical FDA At ODAC Meeting

The agency questions the true benefit of the drug in preventing venous thromboembolism in certain cancer patients, even with a more limited population than the sponsor originally asked for.

Onyx’s Kyprolis Heads To ODAC With Open-label Trial; Will Desperation Outweigh Doubts?

Onyx is relying on a single open-label single-arm Phase IIb trial of Kyprolis (carfilzomib) in patients with relapsed and refractory myeloma, which resulted in an overall response rate of 24%

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts